Compare First Trust Cloud Computing ETF (SKYY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Twist Bioscience Corp — how do they compare? First Trust Cloud Computing ETF trades at $161.44, while Twist Bioscience Corp trades at $124.01 (market cap $7.72B). Which is the better fit depends on your goals.
| SKYY | TWST | |
|---|---|---|
52-Week High | $161.09 | $124.88 |
52-Week Low | $104.16 | $24.16 |
Market Cap | — | $7.72B |
Sector | — | Health |
Enterprise Value | — | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Trust Cloud Computing ETF (SKYY) trades at $163.00, up 1.38% with bullish technical signals from moving averages and ADX indicators. The ETF provides diversified exposure to cloud infrastructure, software, and AI companies, benefiting from secular trends in cloud migration and AI adoption. Recent news highlights strong institutional interest in technology ETFs and SKYY's positioning in the expanding AI ecosystem beyond semiconductors.
SKYY offers exposure to cloud computing growth drivers with technical momentum supporting near-term upside. Key risks include technology sector volatility and competitive pressures from global cloud initiatives. The ETF's diversified approach mitigates concentration risk while capturing broader technology transformation trends.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
